QUOTE AND NEWS
FiercePharma  Jun 17  Comment 
BioMarin climbs on rumors it may be Sanofi's Medivation backup chelfand Fri, 06/17/2016 - 12:00
Forbes  Jun 17  Comment 
In early trading on Friday, shares of BioMarin Pharmaceutical (BMRN) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.1%. Year to date, BioMarin Pharmaceutical has lost about 20.5% of its value.
Benzinga  Jun 13  Comment 
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced the termination of the development of BMN-701 for Pompe disease, besides saying that it was planning to out-license the asset. Credit Suisse’s Alethia Young maintained an Outperform rating...
Benzinga  Jun 3  Comment 
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced it has withdrawn Kyndrisa’s marketing authorization application in the EU, following expectations of a negative opinion from CHMP. Barclays’ Geoff Meacham maintained an Overweight...
Benzinga  Jun 1  Comment 
Goldman Sachs remains bullish on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) despite the company withdrawing its EU application for Kyndrisa in Duchenne muscular dystrophy (DMD). The move follows the May 23-26 CHMP meeting which indicated a...
GenEng News  Jun 1  Comment 
BioMarin Pharmaceutical said today it has withdrawn its Marketing Authorization Application (MAA) for Kyndrisa™ (drisapersen), the company’s drug candidate for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. BioMarin said...
newratings.com  Jun 1  Comment 
INDIANAPOLIS (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) has withdrawn its Marketing Authorization Application for Kyndrisa from the European Medicines Agency as the CHMP intended to issue a negative opinion on the Duchenne Muscular Dystrophy...
FierceBiotech  May 31  Comment 
It’s a loser: BioMarin writes off its $680M Duchenne drug gamble john_carroll Tue, 05/31/2016 - 19:38




 

BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.

IMAGE:BMRN-Geography2009.jpg[2]

Competition

BioMarin competes with companies like:

References

  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki